SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics,…

Kura Oncology, Inc. · 8-K filed Sep 9, 2026 at 07:05 ET

At the news

BULLISHIMPACT 6/10

8-K filed Sep 9, 2026 at 07:05 ET

Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and cardiometabolic diseases. Caspian raised $50.0M in a Series A preferred stock private financing, with Kura investing $4.3M, leaving Kura with ~49.2% ownership. Kura contributed assets including KO-7246 and related IP to Caspian in exchange for Caspian common stock and a $1.5M reimbursement, and entered into an intercompany services agreement. This spin-out of a non-core pipeline asset into a separately capitalized entity is a positive catalyst, unlocking value from Kura's menin platform beyond oncology without diluting Kura shareholders.

  • Kura formed subsidiary Caspian Therapeutics to develop next-gen menin inhibitors for diabetes/cardiometabolic diseases.
  • Caspian raised $50.0M in Series A preferred stock financing; Kura invested $4.3M.
  • Kura retains ~49.2% ownership of Caspian post-financing.
  • Kura contributed assets including KO-7246 and related IP to Caspian for shares and up to $1.5M reimbursement.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access